CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Bevacizumab (Avastin)drug
Likely dose
Bevacizumab (Avastin) 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00512876
NCT00512876N/ACompleted
CompareCT.gov

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Walter Reed Army Medical Center·interventional·Posted Aug 8, 2007·Updated Jul 22, 2013

In Brief

A clinical study evaluating Bevacizumab (Avastin) for Corneal Neovascularization. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor, bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal neovascularization.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCorneal Neovascularization
CountriesUnited States
CollaboratorsMassachusetts Eye and Ear Infirmary

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2007
Enrollment StartAug 1, 2007
Primary CompletionJan 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 18.9 years ago

Interventions

Bevacizumab (Avastin)drug

Bevacizumab 10mg/mL 1 drop BID x 3 weeks